60 related articles for article (PubMed ID: 19034280)
1. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.
Benhadji KA; Serova M; Ghoul A; Cvitkovic E; Le Tourneau C; Ogbourne SM; Lokiec F; Calvo F; Hammel P; Faivre S; Raymond E
Br J Cancer; 2008 Dec; 99(11):1808-15. PubMed ID: 19034280
[TBL] [Abstract][Full Text] [Related]
2. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner.
Hampson P; Kavanagh D; Smith E; Wang K; Lord JM; Ed Rainger G
Cancer Immunol Immunother; 2008 Aug; 57(8):1241-51. PubMed ID: 18265980
[TBL] [Abstract][Full Text] [Related]
3. Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.
Freiberger SN; Cheng PF; Iotzova-Weiss G; Neu J; Liu Q; Dziunycz P; Zibert JR; Dummer R; Skak K; Levesque MP; Hofbauer GF
Mol Cancer Ther; 2015 Sep; 14(9):2132-42. PubMed ID: 26116359
[TBL] [Abstract][Full Text] [Related]
4. PKCδ promotes the invasion and migration of colorectal cancer through c-myc/NDRG1 pathway.
Jia HT; Shao YF; Zhou XL; Yang G; Huang L; Aikemu B; Li SC; Ding CS; Fan XD; Hong HJ; Zhang S; Pan RJ; Sun J
Front Oncol; 2023; 13():1026561. PubMed ID: 36816970
[TBL] [Abstract][Full Text] [Related]
5. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
[TBL] [Abstract][Full Text] [Related]
6. New Supramolecular Drug Carriers: The Study of Organogel Conjugated Gold Nanoparticles.
Kowalczuk J; Łapiński A; Stolarczyk E; Demchuk OM; Kubiński K; Janeczko M; Martyna A; Masłyk M; Turczyniak-Surdacka S
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946545
[TBL] [Abstract][Full Text] [Related]
7. Crucial Role of Reactive Oxygen Species (ROS) for the Proapoptotic Effects of Indirubin Derivatives in Cutaneous SCC Cells.
Zhu J; Langer P; Ulrich C; Eberle J
Antioxidants (Basel); 2021 Sep; 10(10):. PubMed ID: 34679649
[TBL] [Abstract][Full Text] [Related]
8. PKCδ/MAPKs and NF-κB Pathways are Involved in the Regulation of Ingenane-Type Diterpenoids from
Jiang M; Xue Y; Li J; Rao K; Yan S; Li H; Chen X; Li R; Liu D
J Inflamm Res; 2021; 14():2681-2696. PubMed ID: 34234502
[TBL] [Abstract][Full Text] [Related]
9. Targeting Cutaneous T-Cell Lymphoma Cells by Ingenol Mebutate (PEP005) Correlates with PKCδ Activation, ROS Induction as Well as Downregulation of XIAP and c-FLIP.
Sumarni U; Reidel U; Eberle J
Cells; 2021 Apr; 10(5):. PubMed ID: 33922439
[TBL] [Abstract][Full Text] [Related]
10. Functional proteomic analysis reveals roles for PKCδ in regulation of cell survival and cell death: Implications for cancer pathogenesis and therapy.
Speidel JT; Affandi T; Jones DNM; Ferrara SE; Reyland ME
Adv Biol Regul; 2020 Dec; 78():100757. PubMed ID: 33045516
[TBL] [Abstract][Full Text] [Related]
11. Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy.
Pardons M; Fromentin R; Pagliuzza A; Routy JP; Chomont N
Cell Rep; 2019 Nov; 29(9):2783-2795.e5. PubMed ID: 31775045
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.
Skroza N; Bernardini N; Proietti I; Potenza C
Ther Clin Risk Manag; 2018; 14():1879-1885. PubMed ID: 30323610
[TBL] [Abstract][Full Text] [Related]
13. Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application.
Seca AML; Pinto DCGA
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29337925
[TBL] [Abstract][Full Text] [Related]
14. 13-Oxyingenol dodecanoate, a cytotoxic ingenol derivative, induces mitochondrial apoptosis and caspase-dependent Akt decrease in K562 cells.
Liu M; Zhang W; Wang G; Song X; Zhao X; Wang X; Qi X; Li J
Tumour Biol; 2016 May; 37(5):6227-38. PubMed ID: 26615422
[TBL] [Abstract][Full Text] [Related]
15. Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms.
Moore CR; Edwards SK; Xie P
J Cancer Sci Ther; 2015 Feb; 7(2):67-74. PubMed ID: 25960828
[TBL] [Abstract][Full Text] [Related]
16. Cancer wars: natural products strike back.
Basmadjian C; Zhao Q; Bentouhami E; Djehal A; Nebigil CG; Johnson RA; Serova M; de Gramont A; Faivre S; Raymond E; Désaubry LG
Front Chem; 2014; 2():20. PubMed ID: 24822174
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.
Jiang G; Mendes EA; Kaiser P; Sankaran-Walters S; Tang Y; Weber MG; Melcher GP; Thompson GR; Tanuri A; Pianowski LF; Wong JK; Dandekar S
AIDS; 2014 Jul; 28(11):1555-66. PubMed ID: 24804860
[TBL] [Abstract][Full Text] [Related]
18. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
19. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.
Berman B
Clin Cosmet Investig Dermatol; 2012; 5():111-22. PubMed ID: 22956883
[TBL] [Abstract][Full Text] [Related]
20. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity.
Ersvaer E; Kittang AO; Hampson P; Sand K; Gjertsen BT; Lord JM; Bruserud O
Toxins (Basel); 2010 Jan; 2(1):174-94. PubMed ID: 22069553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
